The GeneXpert diagnostic testing technology from the US corporation Cepheid, and its parent company Danaher, has revolutionised rapid, accurate diagnosis of tuberculosis (TB) and other diseases, since entering the market in 2010. Yet, due to the high cost of the GeneXpert test cartridges, many countries are not able to scale up testing for all people who need lifesaving diagnosis and subsequent treatment.
MSF and other CSOs sent a letter to Johnson & Johnson, calling on the pharmaceutical corporation not to enforce its secondary patents on TB drug bedaquiline
Gavi must do more to vaccinate children up to age five, and waive co-financing requirements of countries with fragile health systems or in humanitarian crisis
Gilead hikes price while liposomal amphotericin B (L-AmB) for treatment of HIV-related cryptococcal meningitis remains unavailable and unaffordable in countries where it’s most needed
MSF Access Campaign answers three questions on the challenges accessing liposomal amphotericin B (L-AmB), a key drug for treating the deadly HIV opportunistic infection cryptococcal meningitis.